Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05265312 · ClinicalTrials.gov registry record · NA
Implementation and Evaluation of a Diabetes Prevention Clinical Pathway in Primary Care
A NA study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 1,910
- Enrollment target
NCT05265312: Completed NA study, sponsored by Johns Hopkins University.
NCT05265312 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 1,910 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05265312, a NA study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,910 participants
- Enrollment target
Study Summary
Prediabetes is a significant public health problem affecting 88 million U.S. adults. Evidence suggest that the vast majority of people with prediabetes are unaware of having this condition and many are not receiving appropriate care for prediabetes, including referral to evidence-based programs like the Diabetes Prevention Programs (DPP). In the investigator's retrospective cohort study of patients with prediabetes from Johns Hopkins Health Systems, the investigators found that the rates of prediabetes clinical care activities are low. In the investigators' qualitative studies, the investigators found that primary care physician (PCP) barriers include low knowledge about Diabetes Prevention Programs and misperceptions of insurance coverage of these programs and inadequate clinical staff to address prediabetes. Common patient barriers to taking action to prevent diabetes include lack of motivation, time and resources. Based on prior research, comprehensive strategies are urgently needed to improve prediabetes care. Using these findings, the investigators have designed and plan to implement a diabetes prevention clinical pathway which seeks to address some of these common clinician and patient barriers. The investigators hypothesize that the clinical pathway will result in increased clinician screening and intervention and improve patient engagement in diabetes prevention. The investigators will compare results from the intervention clinic compared to a control clinic. If successful, the investigators plan to implement and test the effectiveness of this clinical pathway across the entire health system.
Primary Outcome
Number of PCP visits where ppt referred to Diabetes Prevention Program during intervention period
Interventions
- OTHER START diabetes prevention clinical pathway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,910 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2023-07-02 |
| Phase | NA |
What the finished NCT05265312 record still lists
NCT05265312 is an interventional study that assigns participants to a tested intervention. Its 1,910 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 1 intervention - of which START diabetes prevention clinical pathway is the first listed.
NCT05265312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05265312 about?
NCT05265312 is a clinical study titled "Implementation and Evaluation of a Diabetes Prevention Clinical Pathway in Primary Care". Prediabetes is a significant public health problem affecting 88 million U.S. adults. Evidence suggest that the vast majority of people with prediabetes are unaware of having this condition and many are not receiving appropriate care for prediabetes, including referral to evidence-based programs like...
What is the current status of trial NCT05265312?
This trial is currently completed. It is a NA study. The enrollment target is 1,910 participants. The study started on 2022-05-31. Estimated completion is 2023-07-02.
What interventions are being tested in trial NCT05265312?
The interventions under investigation include: START diabetes prevention clinical pathway (OTHER).
Who is sponsoring clinical trial NCT05265312?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05265312's enrollment target sits among peer trials
1,910 55th of 2000 higher than 1,946 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI